Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Investments (2016 - 2025)

United Therapeutics (UTHR) has disclosed Long-Term Investments for 17 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • Quarterly Long-Term Investments rose 20.43% to $1.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, up 20.43% year-over-year, with the annual reading at $1.8 billion for FY2025, 20.43% up from the prior year.
  • Long-Term Investments hit $1.8 billion in Q4 2025 for United Therapeutics, up from $1.6 billion in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $2.1 billion in Q3 2023 to a low of $1.3 billion in Q3 2024.
  • Historically, Long-Term Investments has averaged $1.6 billion across 5 years, with a median of $1.6 billion in 2022.
  • Biggest five-year swings in Long-Term Investments: surged 65.15% in 2021 and later plummeted 37.92% in 2024.
  • Year by year, Long-Term Investments stood at $1.6 billion in 2021, then dropped by 20.23% to $1.3 billion in 2022, then soared by 45.1% to $1.9 billion in 2023, then fell by 22.75% to $1.5 billion in 2024, then grew by 20.43% to $1.8 billion in 2025.
  • Business Quant data shows Long-Term Investments for UTHR at $1.8 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.9 billion in Q2 2025.